Findings from the largest prospective WEB pooled dataset strengthen the clinical evidence supporting WEB treatment across distinct ruptured and unruptured aneurysm cohorts.Aliso Viejo, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) — Aliso Viejo, Calif. – August 31, 2026 – Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced two separate peer-reviewed publications reporting 1-year outcomes from the WISE (WEB Implant Safety and Long-term Efficacy) study. The publications report distinct 1-year subgroup analyses: one evaluating patients with ruptured intracranial aneurysms and one evaluating patients with unruptured intracranial aneurysms, both treated with the WEB Device. The launch of the WEB Aneurysm Embolization System helped create the intrasaccular treatment category, and with more than 15 years of clinical experience, Terumo Neuro continues to advance the field through ongoing investment in intrasaccular evidence generation, data collection, and patient outcomes. WISE is the largest prospective, multicenter study evaluating the long-term safety and effectiveness of WEB in a broad global patient population. The study combines data from seven prospective, multicenter, single-arm, core laboratory-adjudicated, Good Clinical Practice (GCP)-compliant studies conducted across Europe, North America, and Asia, with a total of 601 patients, including 143 patients with ruptured aneurysms and 449 patients with unruptured aneurysms.1, 2 “WISE examines patient-level data from 601 patients, pooling and fully reanalyzing safety and effectiveness outcomes across a broad population. All studies contributing to WISE were independently core lab and safety adjudicated, with all 7 studies utilizing the same core lab and the majority using the same clinical events adjudicator, enhancing the meaningfulness of the outcomes,” said Sheila Warner, Sr. Director, Medical Affairs, at Terumo Neuro. Publication of the 1-year ruptured subgroup and unruptured subgroup findings represent an important milestone for WEB clinical evidence. Together, they provide clinical evidence supporting the safety and effectiveness of the WEB device across both ruptured and unruptured aneurysms. Among patients with ruptured wide-neck bifurcation aneurysms, the published 1-year results demonstrated:2 0% rebleeding after WEB treatment through one year.0% treatment-related mortality and 1.6% treatment-related morbidity at one year.97.2% technical success, including 100% technical success in aneurysms measuring 6 mm or smaller.87.5% adequate aneurysm occlusion at one year, increasing to 93.5% in aneurysms measuring 6 mm or smaller.6.5% retreatment rate through one year. Among patients with unruptured wide-neck bifurcation aneurysms, the published 1-year results demonstrated:1 0% aneurysm ruptures after WEB treatment through one year.
